Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Female Sexual Dysfunction - Prescription Drug Pipeline Overview 2007 (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 23/07/2007
- Report Title: Female Sexual Dysfunction - Prescription Drug Pipeline Overview 2007
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 27
Introduction
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
Scope
Comprehensive overview of the FSD pipeline with focus on clinical candidates in development for FSD Analysis of the latest clinical trials results of FSD drug candidates in Phase I to III development Analysis of the challenges and opportunities facing products in Phase III and above with estimates of launch dates. Separation of drugs in development for different patient segments including hypoactive sexual desire disorder and female sexual arousal disorder
Highlights
Despite the relatively large patient population, currently there is just one approved drug treatment for FSD. There is much unmet need among patients and physicians and consequently the report believes there is an opportunity to develop this market to parallel to that of the multi-billion dollar male erectile dysfunction market While Intrinsa has benefited from first-to-market advantage, the drug suffers from several weaknesses that can be targeted by pipeline drug companies. Pipeline products can compete on safety, cost, efficiency, delivery, 'cosmetic elegance' and reduced skin irritation The FDA rejection of Intrinsa for FSD has left a big gap in the market. Depending on the outcome of ongoing clinical trials, there are several appealing inlicensing opportunities for larger companies wishing to unlock the potentially lucrative US market
Reasons to Purchase
Understand the placement of key compounds within the FSD development pipeline Identify challenges to be met and niches to be filled in the FSD market Assess novel mechanisms of action in the early pipeline and their potential for the treatment of FSD
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
Scope
Comprehensive overview of the FSD pipeline with focus on clinical candidates in development for FSD Analysis of the latest clinical trials results of FSD drug candidates in Phase I to III development Analysis of the challenges and opportunities facing products in Phase III and above with estimates of launch dates. Separation of drugs in development for different patient segments including hypoactive sexual desire disorder and female sexual arousal disorder
Highlights
Despite the relatively large patient population, currently there is just one approved drug treatment for FSD. There is much unmet need among patients and physicians and consequently the report believes there is an opportunity to develop this market to parallel to that of the multi-billion dollar male erectile dysfunction market While Intrinsa has benefited from first-to-market advantage, the drug suffers from several weaknesses that can be targeted by pipeline drug companies. Pipeline products can compete on safety, cost, efficiency, delivery, 'cosmetic elegance' and reduced skin irritation The FDA rejection of Intrinsa for FSD has left a big gap in the market. Depending on the outcome of ongoing clinical trials, there are several appealing inlicensing opportunities for larger companies wishing to unlock the potentially lucrative US market
Reasons to Purchase
Understand the placement of key compounds within the FSD development pipeline Identify challenges to be met and niches to be filled in the FSD market Assess novel mechanisms of action in the early pipeline and their potential for the treatment of FSD
Purchase Information There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses Worldpay. Worldpay is part of The Royal Bank of Scotland Group, the 5th biggest banking group in the world. Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
